Τίτλος:
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Objectives: To evaluate the prognostic impact of hypercalcemia in newly diagnosed patients with symptomatic multiple myeloma (MM), especially after the incorporation of new agents. Methods: we analyzed the outcomes of newly diagnosed patients with symptomatic myeloma included in the database of the Greek Myeloma Study Group for the prognostic effect of the presence of hypercalcemia (defined as corrected serum calcium ≥11 mg/dL) at diagnosis. Results: Among 2129 consecutive patients with symptomatic MM, 19.5% presented with hypercalcemia at the time of diagnosis. The presence of hypercalcemia was associated with anemia, thrombocytopenia, lower estimated glomerular filtration rate (eGFR), advanced ISS stage, and presence of lytic lesions. Hypercalcemia was more common in patients with high-risk cytogenetics and was associated with inferior survival across different time periods, age groups, and primary treatments. Hypercalcemia was also associated with a twofold increase in the risk of early death. In patients without available FISH, hypercalcemia could substitute for the presence of high-risk cytogenetics and identify patients with worse prognosis along with ISS stage and elevated serum LDH. Conclusion: Hypercalcemia remains a poor prognostic feature in the era of novel agents despite the improvement in the outcomes of patients who present with elevated calcium. © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Συγγραφείς:
Zagouri, F.
Kastritis, E.
Zomas, A.
Terpos, E.
Katodritou, E.
Symeonidis, A.
Delimpasi, S.
Pouli, A.
Vassilakopoulos, T.P.
Michalis, E.
Giannouli, S.
Kartasis, Z.
Christoforidou, A.
Kokoviadou, K.
Hatzimichael, E.
Gika, D.
Megalakaki, C.
Papaioannou, M.
Kyrtsonis, M.-C.
Konstantopoulos, K.
Dimopoulos, M.A.
the Greek Myeloma Study Group
Περιοδικό:
European Journal of Haematology
Εκδότης:
Wiley-Blackwell Publishing Ltd
Λέξεις-κλειδιά:
antineoplastic agent; bortezomib; calcium; lactate dehydrogenase; lenalidomide; new drug; thalidomide derivative; antineoplastic agent, adult; adverse outcome; aged; anemia; Article; calcium blood level; cancer chemotherapy; cancer diagnosis; cancer patient; cancer prognosis; cancer staging; cancer survival; clinical evaluation; clinical outcome; cytogenetics; disease association; estimated glomerular filtration rate; female; fluorescence in situ hybridization; groups by age; high risk patient; human; hypercalcemia; induction chemotherapy; International Prognostic Scoring System; lactate dehydrogenase blood level; major clinical study; male; median survival time; mortality risk; multiple myeloma; overall survival; priority journal; thrombocytopenia; complication; hypercalcemia; Kaplan Meier method; kidney function test; middle aged; mortality; multiple myeloma; osteolysis; prognosis; treatment outcome; very elderly; young adult, Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hypercalcemia; Kaplan-Meier Estimate; Kidney Function Tests; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteolysis; Prognosis; Treatment Outcome; Young Adult
